EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis

Stamatios Lampsas, Chrysa Agapitou, Evangelos Oikonomou, Gerasimos Siasos, Panagiotis Theodossiadis, Georgios Tsivgoulis, Vaia Lambadiari, Irini Chatziralli

Graefe's Archive for Clinical and Experimental Ophthalmology · 2026

DOI: 10.1007/s00417-026-07291-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2026. Verfasst von Stamatios Lampsas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini stre…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Optic Neuropathy, Ischemic, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) has expanded dramatically worldwide, with semaglutide being one of the most widely utilized agents. Nonarteritic anterior ischemic optic neuropathy (NAION) has been associated with GLP-1RAs use from emerging pharmacovigilance data. This systematic review and meta-analysis sought to evaluate the risk of NAION in patients with type 2 diabetes mellitus (T2DM). METHODS: A literature search was made up to September 2025 (PROSPERO: CRD420251155026). Results were synthesized following the PRISMA guidelines and are presented as pooled Hazard Ratios (HR) with 95% confidence intervals (CI). RESULTS: Twelve studies were included; eight retrospective cohorts (14,255,247 participants) were meta-analyzed, with a mean age of 59.3 ± 15.9 years and 32.7% males. Patients with T2DM using semaglutide compared to non-GLP-1RAs showed an increased risk of NAION at 1-year follow-up with a pooled HR of 3.36 (95% CI: 1.44-7.84; p < 0.001; I2 = 97%). At 2-year follow-up, the pooled HR was 2.37 (95% CI: 1.46-3.85; p < 0.001; I² = 0%). The 3-year risk after the sensitivity analysis showed a pooled HR of 2.37 (95% CI: 1.45-3.87, p < 0.001; I² = 28%), and the 5-year pooled HR was 2.37 (95% CI: 0.62-3.92; p < 0.001; I² = 0%). CONCLUSION: This meta-analysis indicates a significant association between semaglutide use and NAION in patients with T2DM compared to non-GLP-1RAs, with this association remaining significant even after 5-years of semaglutide use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesOptic Neuropathy, IschemicHypoglycemic AgentsHumansSemaglutideRisk Factors

Stichwörter der Autor:innen

GLP-1 receptor agonistsNon-Arteritic Anterior Ischemic Optic Neuropathy (NAION)SemaglutideType 2 diabetes mellitus

Substanzen

SemaglutideGlucagon-Like PeptidesHypoglycemic Agents

Autor:innen und Institutionen

  • Second Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini street, Haidari, Athens, 12462, Greece.
  • Third Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, "Sotiria" General Hospital, Athens, 11527, Greece.
  • Cardiovascular Division, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Second Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, 12462, Greece.
  • Second Department of Internal Medicine, Research Institute and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, 12462, Greece.
  • Second Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini street, Haidari, Athens, 12462, Greece. eirchat@yahoo.gr.

Zitieren

APA

Lampsas, S., Agapitou, C., Oikonomou, E., Siasos, G., Theodossiadis, P., Tsivgoulis, G., Lambadiari, V., & Chatziralli, I. (2026). Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-026-07291-4

Vancouver

Lampsas S, Agapitou C, Oikonomou E, Siasos G, Theodossiadis P, Tsivgoulis G, et al. Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology. 2026. doi:10.1007/s00417-026-07291-4

BibTeX
@article{Lampsas2026,
  author = {Lampsas, Stamatios and Agapitou, Chrysa and Oikonomou, Evangelos and Siasos, Gerasimos and Theodossiadis, Panagiotis and Tsivgoulis, Georgios and Lambadiari, Vaia and Chatziralli, Irini},
  title = {Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis},
  journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
  year = {2026},
  doi = {10.1007/s00417-026-07291-4}
}
Kostenlos starten →